Some of pharma’s biggest players — including Merck, Amgen, Abbvie, and Gilead — formed an alliance to fight looming M&A reforms.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The weight loss drug market could be worth $100 billion in the next few years. Naturally, other companies want in.
US equity ETFS saw nearly $150 billion in inflows last month. Those tied to Europe, Japan, and emerging markets weren’t so lucky.
By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals’ dominance in the GLP-1 space.
If similar cases are a guide, the US has given equal weight to both known and hypothetical threats to national security.